Dosing & Uses
Dosage Forms & Strengths
nebulizer solution
- 15mcg/2mL
Chronic Obstructive Pulmonary Disease
15 mcg inhaled via nebulization twice daily (AM & PM)
Not to exceed 30 mcg/day
Renal Impairment
Dose adjustment not necessary
Hepatic Impairment
Use caution; systemic drug exposure prolonged; dose adjustment not necessary
Saftety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (2)
- cisapride
arformoterol and cisapride both increase QTc interval. Contraindicated.
- thioridazine
arformoterol and thioridazine both increase QTc interval. Contraindicated.
Serious - Use Alternative (35)
- adagrasib
adagrasib, arformoterol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- amisulpride
arformoterol and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- amitriptyline
amitriptyline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amoxapine
amoxapine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- clomipramine
clomipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- desipramine
desipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- doxepin
doxepin, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- fexinidazole
fexinidazole and arformoterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
- formoterol
arformoterol and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
- foscarnet
arformoterol and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.
- glasdegib
arformoterol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and arformoterol both increase QTc interval. Avoid or Use Alternate Drug.
- imipramine
imipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- indacaterol, inhaled
arformoterol and indacaterol, inhaled both increase QTc interval. Avoid or Use Alternate Drug.
- inotuzumab
inotuzumab and arformoterol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- isocarboxazid
isocarboxazid increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- ivosidenib
ivosidenib and arformoterol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- lefamulin
lefamulin and arformoterol both increase QTc interval. Avoid or Use Alternate Drug.
- linezolid
linezolid increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- lofepramine
lofepramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- lopinavir
arformoterol and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
macimorelin and arformoterol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- maprotiline
maprotiline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- mobocertinib
mobocertinib and arformoterol both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
- nortriptyline
nortriptyline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ondansetron
arformoterol and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
- panobinostat
arformoterol and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- phenelzine
phenelzine increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- pimozide
arformoterol and pimozide both increase QTc interval. Contraindicated.
- protriptyline
protriptyline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- tranylcypromine
tranylcypromine increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- trazodone
trazodone, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- trimipramine
trimipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- umeclidinium bromide/vilanterol inhaled
arformoterol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vilanterol/fluticasone furoate inhaled
arformoterol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
Monitor Closely (341)
- acebutolol
acebutolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
acebutolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - aceclofenac
aceclofenac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- acemetacin
acemetacin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- albuterol
albuterol and arformoterol both decrease serum potassium. Use Caution/Monitor.
albuterol and arformoterol both decrease sedation. Use Caution/Monitor.
albuterol and arformoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - alfentanil
alfentanil increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfuzosin
arformoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and arformoterol both increase QTc interval. Use Caution/Monitor. - alprazolam
alprazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- amiloride
amiloride increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- amiodarone
arformoterol and amiodarone both increase QTc interval. Use Caution/Monitor.
- amitriptyline
amitriptyline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and amitriptyline both increase QTc interval. Use Caution/Monitor. - amobarbital
amobarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- amoxapine
amoxapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- anagrelide
arformoterol and anagrelide both increase QTc interval. Use Caution/Monitor.
- apomorphine
apomorphine and arformoterol both increase QTc interval. Use Caution/Monitor.
- aripiprazole
aripiprazole increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
aripiprazole and arformoterol both increase QTc interval. Use Caution/Monitor. - armodafinil
arformoterol and armodafinil both decrease sedation. Use Caution/Monitor.
- arsenic trioxide
arformoterol and arsenic trioxide both increase QTc interval. Use Caution/Monitor.
- artemether
artemether and arformoterol both increase QTc interval. Use Caution/Monitor.
- artemether/lumefantrine
arformoterol and artemether/lumefantrine both increase QTc interval. Use Caution/Monitor.
- asenapine
arformoterol and asenapine both increase QTc interval. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and arformoterol both increase QTc interval. Use Caution/Monitor.
- aspirin
aspirin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aspirin rectal
aspirin rectal increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- atenolol
atenolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
atenolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - atomoxetine
arformoterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .
atomoxetine and arformoterol both increase QTc interval. Use Caution/Monitor. - azelastine
azelastine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- azithromycin
azithromycin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- bedaquiline
arformoterol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- belladonna and opium
belladonna and opium increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- bendroflumethiazide
arformoterol and bendroflumethiazide both decrease serum potassium. Use Caution/Monitor.
- benperidol
benperidol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benzphetamine
arformoterol and benzphetamine both decrease sedation. Use Caution/Monitor.
arformoterol and benzphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - betaxolol
betaxolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
betaxolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - bisoprolol
bisoprolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
bisoprolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - brompheniramine
brompheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- bumetanide
arformoterol and bumetanide both decrease serum potassium. Use Caution/Monitor.
- buprenorphine
arformoterol and buprenorphine both increase QTc interval. Use Caution/Monitor.
- buprenorphine buccal
buprenorphine buccal increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
buprenorphine buccal and arformoterol both increase QTc interval. Use Caution/Monitor. - buprenorphine subdermal implant
buprenorphine subdermal implant and arformoterol both increase QTc interval. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and arformoterol both increase QTc interval. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and arformoterol both increase QTc interval. Use Caution/Monitor.
- butabarbital
butabarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- butalbital
butalbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- butorphanol
butorphanol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- caffeine
arformoterol and caffeine both decrease sedation. Use Caution/Monitor.
- carbenoxolone
arformoterol and carbenoxolone both decrease serum potassium. Use Caution/Monitor.
- carbinoxamine
carbinoxamine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carvedilol
carvedilol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
carvedilol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - celecoxib
celecoxib increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- celiprolol
celiprolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
celiprolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - ceritinib
ceritinib and arformoterol both increase QTc interval. Use Caution/Monitor.
- chloral hydrate
chloral hydrate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chloroquine
chloroquine increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- chlorothiazide
arformoterol and chlorothiazide both decrease serum potassium. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
chlorpromazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and chlorpromazine both increase QTc interval. Use Caution/Monitor. - chlorthalidone
arformoterol and chlorthalidone both decrease serum potassium. Use Caution/Monitor.
- choline magnesium trisalicylate
choline magnesium trisalicylate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- cinnarizine
cinnarizine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ciprofloxacin
arformoterol and ciprofloxacin both increase QTc interval. Use Caution/Monitor.
- citalopram
arformoterol and citalopram both increase QTc interval. Use Caution/Monitor.
- clarithromycin
arformoterol and clarithromycin both increase QTc interval. Use Caution/Monitor.
- clemastine
clemastine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clomipramine
clomipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clonazepam
clonazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clorazepate
clorazepate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- clozapine
clozapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and clozapine both increase QTc interval. Use Caution/Monitor. - codeine
codeine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- crizotinib
arformoterol and crizotinib both increase QTc interval. Use Caution/Monitor.
- cyclizine
cyclizine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cyclopenthiazide
arformoterol and cyclopenthiazide both decrease serum potassium. Use Caution/Monitor.
- cyproheptadine
cyproheptadine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dasatinib
arformoterol and dasatinib both increase QTc interval. Use Caution/Monitor.
- deflazacort
arformoterol and deflazacort both decrease serum potassium. Use Caution/Monitor.
- degarelix
arformoterol and degarelix both increase QTc interval. Use Caution/Monitor.
- desipramine
desipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and desipramine both increase QTc interval. Use Caution/Monitor. - deutetrabenazine
arformoterol and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dexchlorpheniramine
dexchlorpheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexfenfluramine
arformoterol and dexfenfluramine both decrease sedation. Use Caution/Monitor.
arformoterol and dexfenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dexmedetomidine
dexmedetomidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmethylphenidate
arformoterol and dexmethylphenidate both decrease sedation. Use Caution/Monitor.
arformoterol and dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dextroamphetamine
arformoterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.
arformoterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dextromoramide
dextromoramide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diamorphine
diamorphine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dichlorphenamide
dichlorphenamide and arformoterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, arformoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - diclofenac
diclofenac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diethylpropion
arformoterol and diethylpropion both decrease sedation. Use Caution/Monitor.
arformoterol and diethylpropion both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - difenoxin hcl
difenoxin hcl increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diflunisal
diflunisal increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- digoxin
digoxin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diphenhydramine
diphenhydramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- diphenoxylate hcl
diphenoxylate hcl increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dipipanone
dipipanone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- disopyramide
arformoterol and disopyramide both increase QTc interval. Use Caution/Monitor.
- dobutamine
arformoterol and dobutamine both decrease serum potassium. Use Caution/Monitor.
arformoterol and dobutamine both decrease sedation. Use Caution/Monitor.
arformoterol and dobutamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dofetilide
dofetilide increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- dolasetron
arformoterol and dolasetron both increase QTc interval. Use Caution/Monitor.
- donepezil
donepezil and arformoterol both increase QTc interval. Use Caution/Monitor.
- dopamine
arformoterol and dopamine both decrease sedation. Use Caution/Monitor.
arformoterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - dopexamine
arformoterol and dopexamine both decrease serum potassium. Use Caution/Monitor.
arformoterol and dopexamine both decrease sedation. Use Caution/Monitor.
arformoterol and dopexamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - doxepin
doxepin increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
doxepin and arformoterol both increase QTc interval. Use Caution/Monitor. - dronedarone
arformoterol and dronedarone both increase QTc interval. Use Caution/Monitor.
- droperidol
droperidol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and droperidol both increase QTc interval. Use Caution/Monitor. - drospirenone
drospirenone increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- efavirenz
efavirenz and arformoterol both increase QTc interval. Use Caution/Monitor.
- eliglustat
arformoterol and eliglustat both increase QTc interval. Use Caution/Monitor.
- encorafenib
arformoterol and encorafenib both increase QTc interval. Use Caution/Monitor.
- entrectinib
arformoterol and entrectinib both increase QTc interval. Use Caution/Monitor.
- ephedrine
arformoterol and ephedrine both decrease serum potassium. Use Caution/Monitor.
arformoterol and ephedrine both decrease sedation. Use Caution/Monitor.
arformoterol and ephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - epinephrine
arformoterol and epinephrine both decrease serum potassium. Use Caution/Monitor.
arformoterol and epinephrine both decrease sedation. Use Caution/Monitor.
arformoterol and epinephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - epinephrine racemic
arformoterol and epinephrine racemic both decrease serum potassium. Use Caution/Monitor.
arformoterol and epinephrine racemic both decrease sedation. Use Caution/Monitor.
arformoterol and epinephrine racemic both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - eribulin
arformoterol and eribulin both increase QTc interval. Use Caution/Monitor.
- erythromycin base
arformoterol and erythromycin base both increase QTc interval. Use Caution/Monitor.
- erythromycin ethylsuccinate
arformoterol and erythromycin ethylsuccinate both increase QTc interval. Use Caution/Monitor.
- erythromycin lactobionate
arformoterol and erythromycin lactobionate both increase QTc interval. Use Caution/Monitor.
- erythromycin stearate
arformoterol and erythromycin stearate both increase QTc interval. Use Caution/Monitor.
- escitalopram
escitalopram increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- esmolol
esmolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
esmolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - estazolam
estazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ethacrynic acid
arformoterol and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.
- ethanol
ethanol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- etodolac
etodolac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fenfluramine
arformoterol and fenfluramine both decrease sedation. Use Caution/Monitor.
arformoterol and fenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - fenoprofen
fenoprofen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fexinidazole
arformoterol and fexinidazole both increase QTc interval. Use Caution/Monitor.
- fingolimod
fingolimod and arformoterol both increase QTc interval. Use Caution/Monitor.
- flecainide
arformoterol and flecainide both increase QTc interval. Use Caution/Monitor.
- fluconazole
arformoterol and fluconazole both increase QTc interval. Use Caution/Monitor.
- fluoxetine
arformoterol and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- fluphenazine
fluphenazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and fluphenazine both increase QTc interval. Use Caution/Monitor. - flurazepam
flurazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- flurbiprofen
flurbiprofen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- formoterol
arformoterol and formoterol both decrease serum potassium. Use Caution/Monitor.
arformoterol and formoterol both decrease sedation. Use Caution/Monitor.
arformoterol and formoterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - fostemsavir
arformoterol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- furosemide
arformoterol and furosemide both decrease serum potassium. Use Caution/Monitor.
- gemifloxacin
arformoterol and gemifloxacin both increase QTc interval. Use Caution/Monitor.
- gemtuzumab
arformoterol and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gentamicin
arformoterol and gentamicin both decrease serum potassium. Use Caution/Monitor.
- gilteritinib
gilteritinib and arformoterol both increase QTc interval. Use Caution/Monitor.
- goserelin
goserelin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- granisetron
arformoterol and granisetron both increase QTc interval. Use Caution/Monitor.
- green tea
green tea increases effects of arformoterol by pharmacodynamic synergism. Use Caution/Monitor. Due to caffeine content. Combination may increase CNS stimulatory effects due to caffeine in green tea.
- haloperidol
haloperidol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
haloperidol and arformoterol both increase QTc interval. Use Caution/Monitor. - histrelin
histrelin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- hydrochlorothiazide
arformoterol and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.
- hydromorphone
hydromorphone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydroxyzine
hydroxyzine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and hydroxyzine both increase QTc interval. Use Caution/Monitor. - ibuprofen
ibuprofen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ibuprofen IV
ibuprofen IV increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ibutilide
arformoterol and ibutilide both increase QTc interval. Use Caution/Monitor.
- iloperidone
iloperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and iloperidone both increase QTc interval. Use Caution/Monitor. - imipramine
imipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- indapamide
arformoterol and indapamide both decrease serum potassium. Use Caution/Monitor.
- indomethacin
indomethacin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- isoflurane
arformoterol and isoflurane both increase QTc interval. Use Caution/Monitor.
- isoproterenol
arformoterol and isoproterenol both decrease serum potassium. Use Caution/Monitor.
arformoterol and isoproterenol both decrease sedation. Use Caution/Monitor.
arformoterol and isoproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - isradipine
arformoterol and isradipine both increase QTc interval. Use Caution/Monitor.
- itraconazole
arformoterol and itraconazole both increase QTc interval. Use Caution/Monitor.
- ketoprofen
ketoprofen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketorolac
ketorolac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketorolac intranasal
ketorolac intranasal increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- ketotifen, ophthalmic
ketotifen, ophthalmic increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- labetalol
labetalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
labetalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - lapatinib
arformoterol and lapatinib both increase QTc interval. Use Caution/Monitor.
- lenvatinib
arformoterol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levalbuterol
arformoterol and levalbuterol both decrease serum potassium. Use Caution/Monitor.
arformoterol and levalbuterol both decrease sedation. Use Caution/Monitor.
arformoterol and levalbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - levofloxacin
arformoterol and levofloxacin both increase QTc interval. Use Caution/Monitor.
- levorphanol
levorphanol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lisdexamfetamine
arformoterol and lisdexamfetamine both decrease sedation. Use Caution/Monitor.
arformoterol and lisdexamfetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - lithium
arformoterol and lithium both increase QTc interval. Use Caution/Monitor.
- lofepramine
lofepramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofexidine
lofexidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and lofexidine both increase QTc interval. Use Caution/Monitor. - loperamide
arformoterol and loperamide both increase QTc interval. Use Caution/Monitor.
- loprazolam
loprazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lorazepam
lorazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lormetazepam
lormetazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lornoxicam
lornoxicam increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- loxapine
loxapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- loxapine inhaled
loxapine inhaled increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- maprotiline
maprotiline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and maprotiline both increase QTc interval. Use Caution/Monitor. - marijuana
marijuana increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meclofenamate
meclofenamate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mefenamic acid
mefenamic acid increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mefloquine
arformoterol and mefloquine both increase QTc interval. Use Caution/Monitor.
- melatonin
melatonin increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meloxicam
meloxicam increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meperidine
meperidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- meprobamate
meprobamate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaproterenol
arformoterol and metaproterenol both decrease serum potassium. Use Caution/Monitor.
arformoterol and metaproterenol both decrease sedation. Use Caution/Monitor.
arformoterol and metaproterenol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methadone
methadone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and methadone both increase QTc interval. Use Caution/Monitor. - methamphetamine
arformoterol and methamphetamine both decrease sedation. Use Caution/Monitor.
arformoterol and methamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methyclothiazide
arformoterol and methyclothiazide both decrease serum potassium. Use Caution/Monitor.
- methylenedioxymethamphetamine
arformoterol and methylenedioxymethamphetamine both decrease sedation. Use Caution/Monitor.
arformoterol and methylenedioxymethamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - methylphenidate
arformoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- metolazone
arformoterol and metolazone both decrease serum potassium. Use Caution/Monitor.
- metoprolol
metoprolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metoprolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - midazolam
midazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midodrine
arformoterol and midodrine both decrease sedation. Use Caution/Monitor.
arformoterol and midodrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - midostaurin
arformoterol and midostaurin both increase QTc interval. Use Caution/Monitor.
- mifepristone
mifepristone, arformoterol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- mirtazapine
mirtazapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and mirtazapine both increase QTc interval. Use Caution/Monitor. - modafinil
arformoterol and modafinil both decrease sedation. Use Caution/Monitor.
- morphine
morphine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- motherwort
motherwort increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- moxifloxacin
arformoterol and moxifloxacin both increase QTc interval. Use Caution/Monitor.
- moxonidine
moxonidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nabilone
nabilone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nabumetone
nabumetone increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nadolol
nadolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
nadolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - nalbuphine
nalbuphine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- naproxen
naproxen increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nebivolol
nebivolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
nebivolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - nilotinib
arformoterol and nilotinib both increase QTc interval. Use Caution/Monitor.
- norepinephrine
arformoterol and norepinephrine both decrease serum potassium. Use Caution/Monitor.
arformoterol and norepinephrine both decrease sedation. Use Caution/Monitor.
arformoterol and norepinephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - nortriptyline
nortriptyline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and nortriptyline both increase QTc interval. Use Caution/Monitor. - octreotide
arformoterol and octreotide both increase QTc interval. Use Caution/Monitor.
- ofloxacin
arformoterol and ofloxacin both increase QTc interval. Use Caution/Monitor.
- olanzapine
olanzapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances - olodaterol inhaled
arformoterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effects
arformoterol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. - opium tincture
opium tincture increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- osilodrostat
osilodrostat and arformoterol both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and arformoterol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of arformoterol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
arformoterol and oxaliplatin both increase QTc interval. Use Caution/Monitor. - oxaprozin
oxaprozin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxazepam
oxazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxycodone
oxycodone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- oxymorphone
oxymorphone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ozanimod
ozanimod and arformoterol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
paliperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and paliperidone both increase QTc interval. Use Caution/Monitor. - papaveretum
papaveretum increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- papaverine
papaverine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- parecoxib
parecoxib increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pasireotide
arformoterol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- pazopanib
arformoterol and pazopanib both increase QTc interval. Use Caution/Monitor.
- penbutolol
penbutolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
penbutolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - pentazocine
pentazocine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pentobarbital
pentobarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- perphenazine
perphenazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and perphenazine both increase QTc interval. Use Caution/Monitor. - phendimetrazine
arformoterol and phendimetrazine both decrease sedation. Use Caution/Monitor.
arformoterol and phendimetrazine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - phenobarbital
phenobarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenoxybenzamine
phenoxybenzamine, arformoterol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Hypotension, tachycardia.
- phentermine
arformoterol and phentermine both decrease sedation. Use Caution/Monitor.
arformoterol and phentermine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - phenylephrine
arformoterol and phenylephrine both decrease sedation. Use Caution/Monitor.
arformoterol and phenylephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - phenylephrine PO
arformoterol and phenylephrine PO both decrease sedation. Use Caution/Monitor.
arformoterol and phenylephrine PO both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - pholcodine
pholcodine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimavanserin
arformoterol and pimavanserin both increase QTc interval. Use Caution/Monitor.
- pimozide
pimozide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pindolol
pindolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
pindolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - pirbuterol
arformoterol and pirbuterol both decrease serum potassium. Use Caution/Monitor.
arformoterol and pirbuterol both decrease sedation. Use Caution/Monitor.
arformoterol and pirbuterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - piroxicam
piroxicam increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pitolisant
arformoterol and pitolisant both increase QTc interval. Use Caution/Monitor.
- ponesimod
arformoterol and ponesimod both increase QTc interval. Use Caution/Monitor.
- posaconazole
arformoterol and posaconazole both increase QTc interval. Use Caution/Monitor.
- potassium acid phosphate
potassium acid phosphate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- potassium chloride
potassium chloride increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- potassium citrate
potassium citrate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- primaquine
arformoterol and primaquine both increase QTc interval. Use Caution/Monitor.
- primidone
primidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- procainamide
arformoterol and procainamide both increase QTc interval. Use Caution/Monitor.
- procarbazine
procarbazine increases effects of arformoterol by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- prochlorperazine
prochlorperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- promethazine
promethazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- propafenone
arformoterol and propafenone both increase QTc interval. Use Caution/Monitor.
- propranolol
propranolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
propranolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - propylhexedrine
arformoterol and propylhexedrine both decrease sedation. Use Caution/Monitor.
arformoterol and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - protriptyline
protriptyline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and protriptyline both increase QTc interval. Use Caution/Monitor. - pseudoephedrine
arformoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- quazepam
quazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
quetiapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and quetiapine both increase QTc interval. Use Caution/Monitor. - quinidine
arformoterol and quinidine both increase QTc interval. Use Caution/Monitor.
- quinine
arformoterol and quinine both increase QTc interval. Use Caution/Monitor.
- quizartinib
quizartinib, arformoterol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
- ranolazine
arformoterol and ranolazine both increase QTc interval. Use Caution/Monitor.
- ribociclib
ribociclib increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- rilpivirine
arformoterol and rilpivirine both increase QTc interval. Use Caution/Monitor.
- risperidone
risperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and risperidone both increase QTc interval. Use Caution/Monitor. - romidepsin
arformoterol and romidepsin both increase QTc interval. Use Caution/Monitor.
- sacubitril/valsartan
sacubitril/valsartan increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- salicylates (non-asa)
salicylates (non-asa) increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- salmeterol
arformoterol and salmeterol both decrease serum potassium. Use Caution/Monitor.
arformoterol and salmeterol both decrease sedation. Use Caution/Monitor.
arformoterol and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - salsalate
salsalate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- saquinavir
arformoterol and saquinavir both increase QTc interval. Use Caution/Monitor.
- scullcap
scullcap increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- secobarbital
secobarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- selpercatinib
selpercatinib increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.
- serdexmethylphenidate/dexmethylphenidate
arformoterol and serdexmethylphenidate/dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- sertraline
arformoterol and sertraline both increase QTc interval. Use Caution/Monitor.
- sevoflurane
arformoterol and sevoflurane both increase QTc interval. Use Caution/Monitor.
- shepherd's purse
shepherd's purse increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- siponimod
arformoterol and siponimod both increase QTc interval. Use Caution/Monitor.
- sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol
arformoterol and sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.
- solifenacin
arformoterol and solifenacin both increase QTc interval. Use Caution/Monitor.
- solriamfetol
arformoterol and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- sorafenib
sorafenib and arformoterol both increase QTc interval. Use Caution/Monitor.
- sotalol
sotalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
sotalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor.
arformoterol and sotalol both increase QTc interval. Use Caution/Monitor. - spironolactone
spironolactone increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- succinylcholine
succinylcholine increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sufentanil
sufentanil increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sulfasalazine
sulfasalazine increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sulindac
sulindac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sunitinib
arformoterol and sunitinib both increase QTc interval. Use Caution/Monitor.
- tacrolimus
arformoterol and tacrolimus both increase QTc interval. Use Caution/Monitor.
- tapentadol
tapentadol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- telavancin
arformoterol and telavancin both increase QTc interval. Use Caution/Monitor.
- temazepam
temazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- terbutaline
arformoterol and terbutaline both decrease serum potassium. Use Caution/Monitor.
arformoterol and terbutaline both decrease sedation. Use Caution/Monitor.
arformoterol and terbutaline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - tetrabenazine
arformoterol and tetrabenazine both increase QTc interval. Use Caution/Monitor.
- thioridazine
thioridazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thiothixene
thiothixene increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- timolol
timolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
timolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. - tolfenamic acid
tolfenamic acid increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tolmetin
tolmetin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tolvaptan
tolvaptan increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- topiramate
topiramate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- toremifene
arformoterol and toremifene both increase QTc interval. Use Caution/Monitor.
- torsemide
arformoterol and torsemide both decrease serum potassium. Use Caution/Monitor.
- tramadol
tramadol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trazodone
trazodone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and trazodone both increase QTc interval. Use Caution/Monitor. - triamterene
triamterene increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- triazolam
triazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- triclabendazole
arformoterol and triclabendazole both increase QTc interval. Use Caution/Monitor.
- triclofos
triclofos increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trifluoperazine
trifluoperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- trimipramine
trimipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and trimipramine both increase QTc interval. Use Caution/Monitor. - triprolidine
triprolidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- triptorelin
triptorelin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- valbenazine
valbenazine and arformoterol both increase QTc interval. Use Caution/Monitor.
- vandetanib
arformoterol and vandetanib both increase QTc interval. Use Caution/Monitor.
- vardenafil
arformoterol and vardenafil both increase QTc interval. Use Caution/Monitor.
- vemurafenib
arformoterol and vemurafenib both increase QTc interval. Use Caution/Monitor.
- voclosporin
voclosporin, arformoterol. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
arformoterol and voriconazole both increase QTc interval. Use Caution/Monitor.
- vorinostat
arformoterol and vorinostat both increase QTc interval. Use Caution/Monitor.
- xylometazoline
arformoterol and xylometazoline both decrease sedation. Use Caution/Monitor.
arformoterol and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - yohimbine
arformoterol and yohimbine both decrease sedation. Use Caution/Monitor.
arformoterol and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. - ziconotide
ziconotide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziprasidone
ziprasidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and ziprasidone both increase QTc interval. Use Caution/Monitor.
Minor (15)
- bendroflumethiazide
arformoterol, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- bumetanide
arformoterol, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- chlorothiazide
arformoterol, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- chlorthalidone
arformoterol, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- cyclopenthiazide
arformoterol, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- ethacrynic acid
arformoterol, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- eucalyptus
eucalyptus increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- furosemide
arformoterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- hydrochlorothiazide
arformoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- indapamide
arformoterol, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- methyclothiazide
arformoterol, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- metolazone
arformoterol, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
- noni juice
noni juice increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- sage
sage increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- torsemide
arformoterol, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.
Adverse Effects
1-10%
Back pain (6%)
Chest pain (7%)
Diarrhea (6%)
Dyspnea (4%)
Flu syndrome (3%)
Leg cramps (4%)
Lung disorder (2%)
Pain (8%)
Peripheral edema (3%)
Rash (4%)
Sinusitis (5%)
Warnings
Contraindications
Hypersensitivity to arformoterol or formoterol, or any ingredients
Treatment of asthma without a concomitant long-term asthma control medication, such as an inhaled corticosteroid
Cautions
Use only if not adequately controlled by asthma controller medications
Use only for shortest duration of time
Immediate hypersensitivity reactions may occur after administration of arformoterol inhalation solution as demonstrated by cases of anaphylactic reaction, urticaria, angioedema, rash and bronchospasm
Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects; the decrease in serum potassium is usually transient, not requiring supplementation
Beta-agonist medications may produce transient hyperglycemia in some patients; clinically significant and dose-related changes in serum potassium and blood glucose were infrequent during clinical trials with long-term administration of arformoterol inhalation Solution at recommended dose
Use caution in patients with coexisting conditions, including convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to sympathomimetic amines; doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis
As with other inhaled beta2-agonists, arformoterol inhalation solution can produce paradoxical bronchospasm that may be life-threatening; if paradoxical bronchospasm occurs, arformoterol inhalation solution should be discontinued immediately and alternative therapy instituted
Fatalities reported in association with excessive use of inhaled sympathomimetic drugs; as with other inhaled beta2-adrenergic drugs, arformoterol inhalation solution should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists
Serious Asthma-Related Events
- Safety and efficacy of Inhalation Solution in patients with asthma not established
- Inhalation Solution is not indicated for treatment of asthma
- Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy [without inhaled corticosteroids (ICS)] for asthma is associated with an increased risk of asthma-related death
- Available data from controlled clinical trials suggest that use of LABA as monotherapy increases risk of asthma-related hospitalization in pediatric and adolescent patients
- These findings are considered a class effect of LABA monotherapy; when LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, and death) compared with ICS alone
- No study adequate to determine whether the rate of asthma-related death is increased in patients treated with inhalation solution has been conducted; clinical studies with racemic formoterol suggested a higher incidence of serious asthma exacerbations in patients who received racemic formoterol than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.
- Available data do not suggest an increased risk of death with use of LABA in patients with COPD
Deterioration of disease and acute episodes
- Inhalation solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition
- Use of inhalation solution in this setting is inappropriate; arformoterol inhalation solution is not indicated for treatment of acute episodes of bronchospasm, i.e, as rescue therapy and extra doses should not be used for that purpose
- Acute symptoms should be treated with an inhaled short-acting beta2-agonist; when beginning inhalation solution, patients who have been taking inhaled short-acting beta2-agonists on a regular basis (eg, four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms
- When prescribing inhalation solution, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient how it should be used
- Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated; COPD may deteriorate acutely over a period of hours or chronically over several days or longer
- If inhalation solution no longer controls the symptoms of bronchoconstriction, or the patient’s inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease
- In this setting, a reevaluation of the patient and the COPD treatment regimen should be undertaken at once; increasing the daily dosage of inhalation solution beyond recommended 15 mcg twice daily dose is not appropriate in this situation
Cardiovascular effects
- Arformoterol inhalation solution, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic and/or diastolic blood pressure, and/or symptoms
- If such effects occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST-segment depression; use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
- Arformoterol inhalation solution, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
Pregnancy & Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women; drug should only be used during pregnancy if expected benefit outweighs potential risk to fetus; women should be advised to contact their physician if they become pregnant while receiving therapy
The potential effect of therapy on labor and delivery is unknown; because of potential for beta-agonists interference with uterine contractility, use of inhalation solution during labor should be restricted to whom benefits clearly outweigh risk
Animal data
- In animal reproduction studies with rats and rabbits at exposures approximately 370 and 8,400 times adult exposure at maximum recommended human daily inhalation dose (MRHDID) of 15 mcg every 12 hours, respectively, there were findings of structural abnormalities, embryofetal and infant mortality, and alterations of growth
- Adverse effects generally occurred at large multiples of the MRHDID when drug was administered by oral route to achieve high systemic exposures; no evidence of fetal harm was observed in rabbits at an exposure approximately 4,900 times the MRHDID
Lactation
There are no data on presence of arformoterol or its metabolites in human milk, effects on breastfed infant, or on milk production; however, arformoterol was excreted in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Long-acting beta2-agonist, R,R-enantiomer of racemic formoterol; relaxes bronchial smooth muscle by acting selectively on beta2-receptors
Pharmacokinetics
Excretion: Urine (67%); feces (22%)
Onset: 7-20 min
Half-life: 26hr
Peak plasma time: 0.5-3hr
Peak Plasma: 4.3 pg/mL
AUC: 34.5 pg.hr/mL
Protein Bound: 52-65%
Metabolism: uridine diphosphoglucuronosyltransferases (glucuronidation), CYP2D6, CYP2C19 (O-demethylation)
Renal Clearance: 8.9 L/hr
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Brovana inhalation - | 15 mcg/2 mL nebulizer soln |  | |
| Brovana inhalation - | 15 mcg/2 mL nebulizer soln |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
arformoterol inhalation
ARFORMOTEROL SOLUTION - INHALATION
(AR-for-MOE-ter-ol)
COMMON BRAND NAME(S): Brovana
USES: Arformoterol is used as a long-term (maintenance) treatment to prevent and decrease wheezing and shortness of breath caused by breathing problems (such as chronic obstructive pulmonary disease, including chronic bronchitis and emphysema). Arformoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Arformoterol is also known as a bronchodilator. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.This medication does not work right away and should not be used for sudden attacks of breathing trouble. Your doctor must prescribe a quick-relief medicine/inhaler (such as albuterol, also known as salbutamol) for sudden shortness of breath while you are using arformoterol. You should always have a quick-relief inhaler with you.Arformoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as arformoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.
HOW TO USE: Read the Patient Information Leaflet provided by your pharmacist before you start using this medication and each time you get a refill. This medication is used with a special machine called a nebulizer that changes the solution to a fine mist that you inhale. Learn how to prepare the solution and use the nebulizer properly. If a child is using this medication, a parent or other responsible adult may need to help the child use the nebulizer properly. If you have any questions, ask your doctor, pharmacist, or respiratory therapist.This product should be clear and colorless. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid.Using the nebulizer, inhale this medication into your lungs as directed by your doctor, usually 2 times a day (once in the morning and once in the evening). The 2 doses should be about 12 hours apart. Each treatment usually takes about 5 to 10 minutes. Use this medication only through a nebulizer. Do not swallow or inject the solution. Do not mix with other medicines in the nebulizer. To prevent infections, clean the nebulizer and mouthpiece/face mask according to the manufacturer's directions.Use this medication regularly to get the most benefit from it. To help you remember, use it at the same times each day.The dosage is based on your medical condition, age, and response to treatment. Do not use more of this medication or use it more often than prescribed since this may cause serious side effects. Do not use more than 30 micrograms of arformoterol a day.If you have been using a quick-relief inhaler (albuterol, salbutamol) on a regular daily schedule (such as 4 times daily), your doctor will direct you to stop this schedule and only use the quick-relief inhaler as needed for sudden shortness of breath. Consult your doctor for details.Learn which of your inhalers/medications you should use every day and which you should use if your breathing suddenly worsens (quick-relief drugs). Ask your doctor ahead of time what you should do if you have new or worsening cough or shortness of breath, wheezing, increased sputum, worsening peak flow meter readings, waking up at night with trouble breathing, if you use your quick-relief inhaler more often (more than 2 days a week), or if your quick-relief inhaler does not seem to be working well. Learn when you can treat sudden breathing problems by yourself and when you must get medical help right away.Tell your doctor if your symptoms do not improve or if they worsen.
SIDE EFFECTS: Nervousness, dizziness, shaking (tremor), headache, nausea, dry mouth, or trouble sleeping may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.This medication may raise your blood pressure. Check your blood pressure regularly and tell your doctor if the results are high.Tell your doctor right away if you have any serious side effects, including: muscle cramps/weakness, increased thirst/urination.Get medical help right away if you have any very serious side effects, including: chest pain, rapid breathing, confusion, fast/irregular heartbeat, severe dizziness, fainting.Rarely, this medication has caused severe (possibly fatal), sudden worsening of breathing problems (paradoxical bronchospasm). If you have trouble breathing or sudden wheezing, use your quick-relief inhaler and get medical help right away.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using arformoterol, tell your doctor or pharmacist if you are allergic to it; or to formoterol; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: diabetes, heart problems (such as irregular heartbeat, angina, previous heart attack), high blood pressure, liver problems, seizures, overactive thyroid (hyperthyroidism), swelling of an artery (aneurysm), a certain tumor of the adrenal gland (pheochromocytoma).Arformoterol may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using arformoterol, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using arformoterol safely.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially QT prolongation (see above).During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Do not use other LABA drugs (such as formoterol, salmeterol) while using this medication.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: chest pain, fast/irregular heartbeat, severe dizziness, fainting.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as blood pressure, heart rate, EKG) may be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.Avoid allergens/irritants that can worsen breathing problems, such as smoke, pollen, pet dander, dust, or molds.Learn to use a peak flow meter, use it daily, and promptly report worsening breathing problems (such as readings in the yellow/red range, increased use of quick-relief inhalers).Because the flu virus can worsen breathing problems, ask your doctor or pharmacist if you should have a flu shot every year.
MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store this medication in the refrigerator away from light. Store in the sealed protective pouch until ready to use. After opening the pouch, store the unused vials back in the pouch. After opening a vial, use the medication right away. Throw away any vials if the solution is discolored. Keep all medications away from children and pets.Unopened pouches of medication may also be stored at room temperature for up to 6 weeks. If stored at room temperature, use/discard the medication within 6 weeks.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).
Information last revised December 2022. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
